Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer.

Yaal-Hahoshen N, Maimon Y, Siegelmann-Danieli N, Lev-Ari S, Ron IG, Sperber F, Samuels N, Shoham J, Merimsky O.

Oncologist. 2011;16(9):1197-202. doi: 10.1634/theoncologist.2011-0150. Epub 2011 Jun 28.

2.

Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202).

Mooiman KD, Goey AK, Meijerman I, Beijnen JH, Schellens JH.

Oncologist. 2012;17(5):740-1; author reply 742-3. doi: 10.1634/theoncologist.2011-0413. Epub 2012 Apr 17. No abstract available.

3.

Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: Implications for cancer treatment.

Cohen Z, Maimon Y, Yoeli-Lerner M, Yang P, Samuels N, Berger R.

Int J Oncol. 2015 Jan;46(1):308-16. doi: 10.3892/ijo.2014.2711. Epub 2014 Oct 17.

PMID:
25333773
4.

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D.

J Clin Oncol. 2011 Jun 20;29(18):2459-65. doi: 10.1200/JCO.2010.31.2975. Epub 2011 May 9.

PMID:
21555686
5.

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, Gori S, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, de Matteis A.

Crit Rev Oncol Hematol. 2008 May;66(2):171-80. Epub 2007 Dec 21.

PMID:
18160303
7.

Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.

Sanna G, Pestrin M, Zafarana E, Biagioni C, Cavaciocchi D, Turner N, Di Leo A, Biganzoli L.

Breast. 2013 Oct;22(5):926-32. doi: 10.1016/j.breast.2013.04.019. Epub 2013 May 22.

PMID:
23707082
8.

[Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer].

Abe H, Umeda T, Tanaka M, Kawai Y, Mori T, Cho H, Kubota Y, Mekata E, Kurumi Y, Tani T.

Gan To Kagaku Ryoho. 2010 Aug;37(8):1483-7. Japanese.

PMID:
20716872
9.

Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients.

Zhang M, Liu X, Li J, He L, Tripathy D.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004921. Review.

PMID:
17443560
10.

Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.

Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C, Sezer O, Possinger K, Flath B.

J Cancer Res Clin Oncol. 2005 Sep;131(9):568-74. Epub 2005 Oct 20.

PMID:
16044345
11.

Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.

Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, Martinotti M, Buononato M, Brunelli A, Lazzarelli S, Donati G, Passalacqua R.

Tumori. 2010 Jan-Feb;96(1):48-53.

12.

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).

Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2014 Dec;148(3):591-7. doi: 10.1007/s10549-014-3202-5. Epub 2014 Nov 16.

PMID:
25399229
13.

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.

Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, Caratení G, Gentile A, Comella G.

Breast Cancer Res Treat. 1998 May;49(1):13-26.

PMID:
9694607
14.

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.

J Clin Oncol. 2008 Feb 1;26(4):592-8. doi: 10.1200/JCO.2007.11.5378.

PMID:
18235117
15.

[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].

Yuan P, Xu BH, Wang JY, Ma F, Li Q, Zhang P, Fan Y, Li Q, Wang WM.

Zhonghua Zhong Liu Za Zhi. 2012 Jun;34(6):465-8. doi: 10. 3760/cma.j.issn.0253-3766.2012.06.014. Chinese.

PMID:
22967451
16.

[Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer].

Guo J, Xu B, Ma F, Fan Y, Yuan P, Wang J, Cai R, Li Q, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2014 May;36(5):372-6. Chinese.

PMID:
25030594
17.

[Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].

Cortés-Flores AO, Morgan-Villela G, Castro-Cervantes JM, Vázquez-Camacho G, Fuentes-Orozco C, González-Ojeda A.

Cir Cir. 2008 Jan-Feb;76(1):23-8. Spanish.

PMID:
18492416
18.

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP.

Cancer. 2007 Sep 1;110(5):965-72.

19.

Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer.

Wielgus KK, Berger AM, Hertzog M.

Oncol Nurs Forum. 2009 Jan;36(1):38-48. doi: 10.1188/09.ONF.38-48.

PMID:
19136337
20.

[The safety of docetaxel with cyclophosphamide (TC) therapy as adjuvant chemotherapy for Japanese women with operable breast cancer].

Tashiro H, Sagawa T, Okada K, Kurokawa T, Soga H, Watanabe R, Yasuoka Y, Honda K, Watanabe Y, Gangi J, Akehi S, Masuda J, Nomoto M; Ehime TC Therapy Study Group.

Gan To Kagaku Ryoho. 2007 Mar;34(3):393-6. Japanese.

PMID:
17353630

Supplemental Content

Support Center